SLSSellas Life Sciences Group Inc.
- Next report
- No date yet
- none in the next 8 weeks
- Price
- $8.13
- −3.44% today · $1.99B cap
Past and upcoming reports
2
| Nov 11, 2026 | Sep 30, 2026 | Time not given | n/a | not recorded | |
| May 19, 2026 | Mar 31, 2026 | Time not given | −$0.07 | not recorded | +23.05%2d |
After the report
Nov 11, 2026 report
SELLAS ended the reported session modestly higher, but the print provided limited incremental fundamental information.
SELLAS closed at $8.43, up 0.66% on 3.82 million shares after trading between $8.09 and $8.59. Reported EPS, guidance, and post-earnings news were unavailable. The forward setup remains dependent on clinical execution and additional institutional disclosures, while 34.5% short interest and a 32.15% one-month decline amplify volatility.
Reported against expected
Reported EPS was not captured, and no EPS estimate was available. therefore, no beat or miss can be established.
Guidance
No company guidance or updated outlook was provided in the available data.
How the stock reacted
The stock closed at $8.425, up $0.055 or 0.66%, with 3,823,570 shares traded. the session range was $8.09-$8.59.
What changed
SELLAS rose 0.66% to $8.43 on 3.82 million shares, with no captured EPS, guidance, or post-earnings news.
What the price now assumes
The muted gain alongside 34.5% short interest suggests cautious positioning around an unproven clinical-growth narrative.
What it means for the business
Keep a speculative, unchanged bias. upgrade only after concrete clinical progress or further institutional disclosures support execution.
The next one to three months, as we saw it then
Better case30%
Additional institutional disclosures and credible clinical progress could validate the growth narrative and challenge substantial short positioning.
Base case45%
The stock remains volatile and range-bound as investors lack captured earnings, guidance, and post-earnings news to re-underwrite fundamentals.
Worse case25%
Failure of clinical execution could undermine the unproven biotech narrative, with heavy short interest increasing downside volatility.
If you hold it
Hold only while the clinical thesis remains supported. trim if clinical progress fails to substantiate growth expectations or ownership disclosures weaken.
If you are watching
Enter only after documented clinical progress or further institutional disclosures. avoid trading while EPS, guidance, and post-earnings news remain unavailable.
Scenario odds are a judgement, not measured.